EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting ANGPTL3 for Lipid Lowering in Atherosclerotic Cardiovascular Disease: A Narrative Review of Genetic, Preclinical and Clinical Evidence

Alexander V. Blagov, Gulalek A. Babayeva, Anastasia O. Maksaeva

International Journal of Molecular Sciences · 19.11.2026 · 27 (22) · 10411

DOI: 10.3390/ijms272210411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.11.2026. Verfasst von Alexander V. Blagov und 2 weiteren Autor:innen. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerotic cardiovascular disease remains the leading cause of death worldwide despite the widespread use of statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A substantial fraction of treated patients retain elevated triglyceride-rich lipoproteins and remnant cholesterol after low-density lipoprotein cholesterol (LDL-C) targets have been met, which has been proposed to contribute to residual cardiovascular risk; however, lowering triglycerides alone has not reliably reduced cardiovascular events, and benefit appears more closely tied to the reduction in apolipoprotein B (apoB)-containing particles. Angiopoietin-like protein 3 (ANGPTL3), a hepatically secreted regulator of lipoprotein lipase and endothelial lipase, has emerged as a mechanistically distinct target that lowers triglycerides, LDL-C, and high-density lipoprotein cholesterol (HDL-C) independently of the LDL receptor (LDLR). This narrative review, based on a structured PubMed/MEDLINE search, synthesizes the structural biology of ANGPTL3, compares ANGPTL3 with PCSK9, ANGPTL4, apolipoprotein C-III (APOC3) and other lipid-lowering therapies, summarizes the preclinical and clinical evidence on its pharmacological inhibition, including the effects of each agent on LDL-C, triglycerides, apoB and non-HDL-C, and discusses the limitations of that evidence and of the review itself. Loss-of-function variants in ANGPTL3 are associated with a lower risk of coronary artery disease in large population cohorts. Pharmacological inhibition has since been tested with several independent modalities, which lower atherogenic lipids but have not been shown to reduce cardiovascular events: monoclonal antibodies (evinacumab, SHR-1918), antisense oligonucleotides (vupanorsen), small interfering RNAs (zodasiran, solbinsiran), and, most recently, in vivo CRISPR-Cas9 gene editing (CTX310). In humans, the evidence for pharmacological inhibition is limited to lipid biomarkers in generally small and short trials; reductions in apoB are consistently smaller than reductions in triglycerides, and evidence of plaque regression derives from animal models only. Each modality carries a distinct efficacy and hepatic safety profile, a divergence (hepatic fat increased with the antisense agent vupanorsen but not with the siRNA agents studied) whose cause—platform chemistry, depth of knockdown, study population or ANGPTL3 biology itself—cannot be determined from the available cross-trial comparisons. We conclude with concrete recommendations for cardiovascular outcome trials, prospective hepatic-fat monitoring, and rational combination strategies with LDLR-dependent agents.

Förderung

  • Russian Science Foundation

Zitieren

APA

Blagov, A. V., Babayeva, G. A., & Maksaeva, A. O. (2026). Targeting ANGPTL3 for Lipid Lowering in Atherosclerotic Cardiovascular Disease: A Narrative Review of Genetic, Preclinical and Clinical Evidence. International Journal of Molecular Sciences, 27(22), 10411. https://doi.org/10.3390/ijms272210411

Vancouver

Blagov AV, Babayeva GA, Maksaeva AO. Targeting ANGPTL3 for Lipid Lowering in Atherosclerotic Cardiovascular Disease: A Narrative Review of Genetic, Preclinical and Clinical Evidence. International Journal of Molecular Sciences. 2026;27(22):10411. doi:10.3390/ijms272210411

BibTeX
@article{Blagov2026,
  author = {Blagov, Alexander V. and Babayeva, Gulalek A. and Maksaeva, Anastasia O.},
  title = {Targeting ANGPTL3 for Lipid Lowering in Atherosclerotic Cardiovascular Disease: A Narrative Review of Genetic, Preclinical and Clinical Evidence},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {22},
  pages = {10411},
  doi = {10.3390/ijms272210411}
}
Kostenlos starten →